  6 ADVERSE REACTIONS

  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

 The safety of INLYTA has been evaluated in 715 patients in monotherapy studies, which included 537 patients with advanced  RCC≠B-Not_AE_Candidate . The data described  [see  Adverse Reactions (6.1)  ]  reflect exposure to INLYTA in 359 patients with advanced  RCC≠B-Not_AE_Candidate  who participated in a randomized clinical study versus sorafenib  [see  Clinical Studies (14)  ]  .

 The following risks, including appropriate action to be taken, are discussed in greater detail in other sections of the label  [see  Warnings and Precautions (5.1-5.13)  ]  :  hypertension≠B-OSE_Labeled_AE ,  arterial≠B-OSE_Labeled_AE   thromboembolic≠I-OSE_Labeled_AE   events≠I-OSE_Labeled_AE ,  venous≠B-OSE_Labeled_AE   thromboembolic≠I-OSE_Labeled_AE   events≠I-OSE_Labeled_AE ,  hemorrhage≠B-OSE_Labeled_AE ,  cardiac≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE ,  gastrointestinal≠B-OSE_Labeled_AE   perforation≠I-OSE_Labeled_AE  and fistula formation,  thyroid≠B-OSE_Labeled_AE   dysfunction≠I-OSE_Labeled_AE ,  wound≠B-OSE_Labeled_AE   healing≠I-OSE_Labeled_AE   complications≠I-OSE_Labeled_AE ,  RPLS≠B-OSE_Labeled_AE ,  proteinuria≠B-OSE_Labeled_AE ,  elevation≠B-OSE_Labeled_AE   of≠I-OSE_Labeled_AE   liver≠I-OSE_Labeled_AE   enzymes≠I-OSE_Labeled_AE ,  hepatic≠B-OSE_Labeled_AE   impairment≠I-OSE_Labeled_AE  and  fetal≠B-OSE_Labeled_AE   development≠I-OSE_Labeled_AE .

   EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation. (  6.1  )

   To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  

 

  6.1 Clinical Trials Experience

  The median duration of treatment was 6.4 months (range 0.03 to 22.0) for patients who received INLYTA and 5.0 months (range 0.03 to 20.1) for patients who received sorafenib. Dose modifications or temporary delay of treatment due to an adverse reaction occurred in 199/359 patients (55%) receiving INLYTA and 220/355 patients (62%) receiving sorafenib. Permanent discontinuation due to an adverse reaction occurred in 34/359 patients (9%) receiving INLYTA and 46/355 patients (13%) receiving sorafenib.

 The most common (>=20%) adverse reactions observed following treatment with INLYTA were  diarrhea≠B-OSE_Labeled_AE ,  hypertension≠B-OSE_Labeled_AE ,  fatigue≠B-OSE_Labeled_AE ,  decreased≠B-OSE_Labeled_AE   appetite≠I-OSE_Labeled_AE ,  nausea≠B-OSE_Labeled_AE ,  dysphonia≠B-OSE_Labeled_AE ,  palmar≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  plantar≠I-OSE_Labeled_AE   erythrodysesthesia≠I-OSE_Labeled_AE   (≠I-OSE_Labeled_AE  hand≠I-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  foot≠I-OSE_Labeled_AE  )≠I-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE ,  weight≠B-OSE_Labeled_AE   decreased≠I-OSE_Labeled_AE ,  vomiting≠B-OSE_Labeled_AE ,  asthenia≠B-OSE_Labeled_AE , and  constipation≠B-OSE_Labeled_AE . Table 1 presents adverse reactions reported in >=10% patients who received INLYTA or sorafenib.

 Table 1. Adverse Reactions Occurring in >=10% of Patients Who Received INLYTA or Sorafenib 
 Adverse Reaction [note: Percentages are treatment-emergent, all-causality events]       INLYTA          Sorafenib      
 (N=359)                                       (N=355)       
 All Grades [note: National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0]      Grade 3/4       All Grades        Grade 3/4      
 %                                                %                %                %          
  
  Diarrhea≠B-OSE_Labeled_AE                                         55               11               53                7          
  Hypertension≠B-OSE_Labeled_AE                                     40               16               29               11          
  Fatigue≠B-OSE_Labeled_AE                                          39               11               32                5          
  Decreased≠B-OSE_Labeled_AE   appetite≠I-OSE_Labeled_AE                               34                5               29                4          
  Nausea≠B-OSE_Labeled_AE                                           32                3               22                1          
  Dysphonia≠B-OSE_Labeled_AE                                        31                0               14                0          
  Palmar≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  plantar≠I-OSE_Labeled_AE   erythrodysesthesia≠I-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE         27                5               51               16          
  Weight≠B-OSE_Labeled_AE   decreased≠I-OSE_Labeled_AE                                 25                2               21                1          
  Vomiting≠B-OSE_Labeled_AE                                         24                3               17                1          
  Asthenia≠B-OSE_Labeled_AE                                         21                5               14                3          
  Constipation≠B-OSE_Labeled_AE                                     20                1               20                1          
  Hypothyroidism≠B-OSE_Labeled_AE                                   19               <1                8                0          
  Cough≠B-OSE_Labeled_AE                                            15                1               17                1          
  Mucosal≠B-OSE_Labeled_AE   inflammation≠I-OSE_Labeled_AE                             15                1               12                1          
  Arthralgia≠B-OSE_Labeled_AE                                       15                2               11                1          
  Stomatitis≠B-OSE_Labeled_AE                                       15                1               12               <1          
  Dyspnea≠B-OSE_Labeled_AE                                          15                3               12                3          
  Abdominal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE                                   14                2               11                1          
  Headache≠B-OSE_Labeled_AE                                         14                1               11                0          
  Pain≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   extremity≠I-OSE_Labeled_AE                                13                1               14                1          
  Rash≠B-OSE_Labeled_AE                                             13               <1               32                4          
  Proteinuria≠B-OSE_Labeled_AE                                      11                3                7                2          
  Dysgeusia≠B-OSE_Labeled_AE                                        11                0                8                0          
  Dry≠B-OSE_Labeled_AE   skin≠I-OSE_Labeled_AE                                         10                0               11                0          
  Dyspepsia≠B-OSE_Labeled_AE                                        10                0                2                0          
  Pruritus≠B-OSE_Labeled_AE                                          7                0               12                0          
  Alopecia≠B-OSE_Labeled_AE                                          4                0               32                0          
  Erythema≠B-OSE_Labeled_AE                                          2                0               10               <1          
           Selected adverse reactions (all grades) that were reported in <10% of patients treated with INLYTA included  dizziness≠B-OSE_Labeled_AE  (9%),  upper≠B-OSE_Labeled_AE   abdominal≠I-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE  (8%),  myalgia≠B-OSE_Labeled_AE  (7%),  dehydration≠B-OSE_Labeled_AE  (6%),  epistaxis≠B-OSE_Labeled_AE  (6%),  anemia≠B-OSE_Labeled_AE  (4%),  hemorrhoids≠B-OSE_Labeled_AE  (4%),  hematuria≠B-OSE_Labeled_AE  (3%),  tinnitus≠B-OSE_Labeled_AE  (3%),  lipase≠B-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE  (3%),  glossodynia≠B-OSE_Labeled_AE  (3%),  pulmonary≠B-OSE_Labeled_AE   embolism≠I-OSE_Labeled_AE  (2%),  rectal≠B-OSE_Labeled_AE   hemorrhage≠I-OSE_Labeled_AE  (2%),  hemoptysis≠B-OSE_Labeled_AE  (2%),  deep≠B-OSE_Labeled_AE   vein≠I-OSE_Labeled_AE   thrombosis≠I-OSE_Labeled_AE  (1%),  retinal≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  vein≠I-OSE_Labeled_AE   occlusion≠I-OSE_Labeled_AE /thrombosis (1%),  polycythemia≠B-OSE_Labeled_AE  (1%), and  transient≠B-OSE_Labeled_AE   ischemic≠I-OSE_Labeled_AE   attack≠I-OSE_Labeled_AE  (1%).
 

 Table 2 presents the most common  laboratory≠B-NonOSE_AE   abnormalities≠I-NonOSE_AE  reported in >=10% patients who received INLYTA or sorafenib.

 Table 2. Laboratory Abnormalities Occurring in >=10% of Patients Who Received INLYTA or Sorafenib 
 Laboratory Abnormality                        N         INLYTA        N       Sorafenib    
 All Grades [note: National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0]   Grade 3/4   All Grades  Grade 3/4    
 %                                             %           %           %        
  
 ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase   
  
   Hematology                                                                                                       
  Hemoglobin≠B-OSE_Labeled_AE   decreased≠I-OSE_Labeled_AE                          320          35          <1         316          52          4        
  Lymphocytes≠B-OSE_Labeled_AE   (≠I-OSE_Labeled_AE  absolute≠I-OSE_Labeled_AE  )≠I-OSE_Labeled_AE   decreased≠I-OSE_Labeled_AE              317          33          3          309          36          4        
  Platelets≠B-OSE_Labeled_AE   decreased≠I-OSE_Labeled_AE                           312          15          <1         310          14          0        
  White≠B-OSE_Labeled_AE   blood≠I-OSE_Labeled_AE   cells≠I-OSE_Labeled_AE   decreased≠I-OSE_Labeled_AE                   320          11          0          315          16          <1       
    Chemistry≠B-NonOSE_AE                                                                                                         
  Creatinine≠B-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE                          336          55          0          318          41          <1       
  Bicarbonate≠B-OSE_Labeled_AE   decreased≠I-OSE_Labeled_AE                         314          44          <1         291          43          0        
  Hypocalcemia≠B-OSE_Labeled_AE                                  336          39          1          319          59          2        
  ALP≠B-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE                                 336          30          1          319          34          1        
  Hyperglycemia≠B-OSE_Labeled_AE                                 336          28          2          319          23          2        
  Lipase≠B-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE                              338          27          5          319          46          15       
  Amylase≠B-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE                             338          25          2          319          33          2        
  ALT≠B-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE                                 331          22          <1         313          22          2        
  AST≠B-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE                                 331          20          <1         311          25          1        
  Hypernatremia≠B-OSE_Labeled_AE                                 338          17          1          319          13          1        
  Hypoalbuminemia≠B-OSE_Labeled_AE                               337          15          <1         319          18          1        
  Hyperkalemia≠B-OSE_Labeled_AE                                  333          15          3          314          10          3        
  Hypoglycemia≠B-OSE_Labeled_AE                                  336          11          <1         319          8           <1       
  Hyponatremia≠B-OSE_Labeled_AE                                  338          13          4          319          11          2        
  Hypophosphatemia≠B-OSE_Labeled_AE                              336          13          2          318          49          16       
             Selected  laboratory≠B-NonOSE_AE   abnormalities≠I-NonOSE_AE  (all grades) that were reported in <10% of patients treated with INLYTA included  hemoglobin≠B-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE  (above the upper limit of normal) (9% for INLYTA versus 1% for sorafenib) and  hypercalcemia≠B-OSE_Labeled_AE  (6% for INLYTA versus 2% for sorafenib).

